The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Intrahepatic Cholangiocarcinoma: expert consensus statement
Open accessAbstract
An American Hepato-Pancreato-Biliary Association (AHPBA)-sponsored consensus meeting of expert panellists met on 15 January 2014 to review current evidence on the management of intrahepatic cholangiocarcinoma (ICC) in order to establish practice guidelines and to agree on consensus statements. The treatment of ICC requires a coordinated, multidisciplinary approach to optimize survival. Biopsy is not necessary if the surgeon suspects ICC and is planning curative resection, although biopsy should be obtained before systemic or locoregional therapies are initiated. Assessment of resectability is best accomplished using cross-sectional imaging [computed tomography (CT) or magnetic resonance imaging (MRI)], but the role of positron emission tomography (PET) is unclear. Resectability in ICC is defined by the ability to completely remove the disease while leaving an adequate liver remnant. Extrahepatic disease, multiple bilobar or multicentric tumours, and lymph node metastases beyond the primary echelon are contraindications to resection. Regional lymphadenectomy should be considered a standard part of surgical therapy. In patients with high-risk features, the routine use of diagnostic laparoscopy is recommended. The preoperative diagnosis of combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) by imaging studies is extremely difficult. Surgical resection remains the mainstay of treatment, but survival is worse than in HCC alone. There are no adequately powered, randomized Phase III trials that can provide definitive recommendations for adjuvant therapy for ICC. Patients with high-risk features (lymphovascular invasion, multicentricity or satellitosis, large tumours) should be encouraged to enrol in clinical trials and to consider adjuvant therapy. Cisplatin plus gemcitabine represents the standard-of-care, front-line systemic therapy for metastatic ICC. Genomic analyses of biliary cancers support the development of targeted therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Egner, J. R. (2010) · JAMA · doi:10.1001/jama.2010.1525 · Cited by 5,997
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
The general rules for the clinical and pathological study of primary liver cancer
Liver Cancer Study Group of Japan (1989) · The Japanese Journal of Surgery · doi:10.1007/bf02471576 · Cited by 1,037
Endo, I., Gonen, M., Yopp, A. C., Dalal, K. M., Zhou, Q., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Fong, Y., Schwartz, L., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176c4d3 · Cited by 865
Self-citationde Jong, M. C., Nathan, H., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., Marques, H., Pulitano, C., Barroso, E., Clary, B. M., Aldrighetti, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6519 · Cited by 729
Self-citationAdjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 716
Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract, Takada, T., Amano, H., Yasuda, H., Nimura, Y., Matsushiro, T., Kato, H., Nagakawa, T., & Nakayama, T. (2002) · Cancer · doi:10.1002/cncr.10831 · Cited by 631
Neoptolemos, J. P., Moore, M. J., Cox, T. F., Valle, J. W., Palmer, D. H., McDonald, A. C., Carter, R., Tebbutt, N. C., Dervenis, C., Smith, D., et al. (2012) · JAMA · doi:10.1001/jama.2012.7352 · Cited by 597
Cited by
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411
Banales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,376
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
Cholangiocarcinoma: Recent Advances in Molecular Pathobiology and Therapeutic Approaches
Khosla, D., Misra, S., Chu, P. L., Guan, P., Nada, R., Gupta, R., Kaewnarin, K., Ko, T. K., Heng, H. L., Srinivasalu, V. K., et al. (2024) · Cancers · doi:10.3390/cancers16040801 · Cited by 44
“Thus, in patients of extrahepatic CCA with involved margins and lymph nodes and in patients with positive margins in intrahepatic CCA, the guidelines suggest adjuvant chemoradiotherapy in addition to adjuvant chemotherapy [123–127].”
Background
Metadata
- Authors
- Weber, S. M., Ribero, D., O'Reilly, E. M., Kokudo, N., Miyazaki, M., & Pawlik, T. M.
- Venue
- HPB
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 17
- Issue
- 8
- Pages
- 669-680
- ISSN
- 1365-182X (ISSN-L)
- OpenAlex
- W1846437462
- Cited by
- 472
- References
- 44
- FWCI
- 26.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intrahepatic Cholangiocarcinoma: expert consensus statement. https://app.cochat.ai/papers/10.1111/hpb.12441
- The paper
- Weber, S. M., Ribero, D., O'Reilly, E. M., Kokudo, N., Miyazaki, M., & Pawlik, T. M. (2015). Intrahepatic Cholangiocarcinoma: expert consensus statement. HPB. https://doi.org/10.1111/hpb.12441
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
